Itrapol (Yttrium-90)

Itrapol, containing Yttrium-90, is employed in targeted radionuclide therapy for certain cancers.

• Unresectable liver cancer: provides internal radiation to hepatic tumors, reducing tumor burden.
• Metastatic neuroendocrine tumors: delivers selective beta radiation to metastatic lesions, aiming to control disease progression.
• Hepatocellular carcinoma: offers localized radiation to improve local control when surgery is not feasible.

• Yttrium-90 emits high‑energy beta particles that travel a short distance in tissue, causing DNA double‑strand breaks and cell death. When administered as a microsphere or embolic carrier, the radionuclide becomes lodged in the tumor vasculature, delivering a high radiation dose directly to the malignant cells while sparing surrounding healthy tissue.

Itrapol may be associated with a range of adverse reactions following administration.

Common Side Effects

• Fatigue: transient tiredness experienced after treatment.
• Nausea: mild to moderate upset stomach.
• Abdominal pain: discomfort in the upper abdomen.
• Fever: low‑grade temperature elevation.
• Transient liver enzyme elevation: temporary rise in ALT/AST.
• Mild anemia: slight reduction in hemoglobin levels.

Serious or Rare Side Effects

• Radiation‑induced liver disease: severe hepatic dysfunction.
• Gastrointestinal ulceration: bleeding or perforation of the GI tract.
• Severe thrombocytopenia: markedly low platelet count.
• Pulmonary embolism: blockage of pulmonary arteries.
• Radiation pneumonitis: inflammation of lung tissue.
• Severe infection: opportunistic infections due to immunosuppression.

Prior to using Itrapol, clinicians should observe several safety measures.

• Patient selection: evaluate liver function and tumor burden before administration.
• Radiation safety: implement shielding and handling protocols for staff.
• Pregnancy: avoid use in pregnant patients due to fetal radiation exposure.
• Concurrent chemotherapy: assess additive bone‑marrow toxicity.
• Monitoring: schedule post‑treatment imaging and laboratory tests.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Itrapol can interact with other therapies that affect radiation dose or blood components.

Major Interactions (Avoid)

• Concurrent external beam radiation: may increase cumulative radiation exposure.
• High‑dose chemotherapy: can amplify bone‑marrow suppression.
• Anticoagulants: may raise bleeding risk after embolization.

Moderate Interactions (Monitor Closely)

• Steroids: may modify inflammatory response post‑treatment.
• Angiogenesis inhibitors: could alter vascular targeting of microspheres.
• Renal‑impairment drugs: monitor renal function as clearance may be affected.